Healio Rheuminations Vascular Ehlers Danlos Syndrome for the Rheumatologist, Pt 2: Extra-Cellular Matrix Reloaded
In this episode we explore ways in which the extracellular matrix can be manipulated, including the story of doxycycline, TGF-beta in Marfan syndrome and whether beta blockers can reduce vascular events in vascular EDS.
· Intro 0:12
· Review of previous episode 0:28
· In this episode 2:26
· The pressure against the vessels 4:06
· The pressure against the wall 8:44
· Matrix metalloproteinases 10:16
· Tadpole study – collagen breakdown 10:35
· Tetracycline antibiotics 14:05
· Rat model – periodontal disease and hydroxyproline 14:24
· Chemically modified tetracyclines 20:14
· Mouse model – tetracycline use 22:00
· Tetracyclines and other autoimmune conditions 23:22
· Marfan syndrome 24:45
· Fibrillin and Marfan syndrome 28:48
· TGF-beta 29:36
· Mouse model – Marfan syndrome and fibrillin 31:14
· ARBs and TGF-beta 33:51
· TGF-beta and vascular EDS 37:25
· Back to the mouse model 38:38
· Protein kinase C 39:56
· Summary 40:26
Disclosures: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
References:
Bowen CJ, et al. J Clin Invest. 2020;130:686-698.
Brooke BS. Lancet. 2010;doi:10.1016/S0140-6736(10)61155-5
Dietz HC, et al. Am J Med Genet C Semin Med Genet. 2005;doi:10.1002/ajmg.c.30068.
Dubacher N, et al. Cardiovasc Res. 2020;116:457-465.
Golub LM, et al. SAGE. 1998;doi:10.1177/08959374980120010501.
Gross J, et al. PNAS. 1962;doi:10.1073/pnas.48.6.1014
Habashi JP, et al. Science. 2006;312:117-121.
Morissette R, et al. Circ Cardiovasc Genet. 2014;7:80-88.